Gene Weaver

Genetic medicines are driving a revolution in therapeutics.

The enhanced gene editing/modification capability of the Gene Weaver Technology Platform is set to address the challenges facing the first generation of editing tools used to create the current genetic medicine pipelines across the industry. These challenges include variable site integration, limited size of edit, and low efficiency of manufacture. All of which limit the scope and applicability of these transformative therapeutics.

Gene Weaver Technology Platform is a uniquely programmable enzymatic system for controlled cutting and precision insertion of large payloads. The team has been able to exploit the characteristics of a naturally occurring gene delivery tool to create a fully controllable technology platform that has the flexibility to support a broad range of permanent nucleic acid edits, including large strand insertions.

This disruptive technology facilitates next level controlled genetic cargo integration because of its:

Specificity – using a large recognition region drives precise placement
Programmable – defined engineerable recognition elements within the system allow most, if not all, targets to be tractable
Cargo size – system supports a natural capacity of up to several kilo bytes
Broad cell applicability (Not just cycling cells) – non-reliance on cell homology-directed repair (HR) processes offers potential for post-mitotic cells
Precision outcome – removes reliance on 'traditional' double stranded breaks (DSBs) and hopeful homology-directed repair (HR) approach

This pioneering next generation technology is set to supersede currently available gene editing and insertion tools used to create the current genetic medicine pipelines across the industry.

Gene Weaver Technology Platform has the potential to make new genetic-based therapeutic modalities more durable and affordable.